Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis

Cancer Treatment Reviews

Volumn 37, Issue 4, 2011, Pages 312-320

  Chen, Tao ^a   Xu, Tao ^a   Li, Yang ^a   Liang, Chun ^a   Chen, Juxiang ^a   Lu, Yicheng ^a   Wu, Zonggui ^a   Wu, Shenhong ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Breast cancer; Heart failure; Meta analysis; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; METASTASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ATRIAL FUNCTION; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; RISK FACTORS; VENTRICULAR FUNCTION; WORLD HEALTH;

EID: 79953122738     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.09.001     Document Type: Review

References (39)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
3. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995, 159:19-27.
4. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904.
5. Baselga J., Carbonell X., Castaneda-Soto N.J., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
6. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
7. Perez E.A., Suman V.J., Davidson N.E., et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004, 22:3700-3704.
8. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
9. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
10. Gasparini G., Gion M., Mariani L., et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007, 101:355-365.
11. Buzdar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233.
12. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004, 15:19-27.
13. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:283-290.
14. Lara P.N., Chee K.G., Longmate J., et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004, 100:2125-2131.
15. Genentech. Trastuzumab prescribing information. (accessed 01.08.09). http://www.gene.com/gene/products/information/oncology/herceptin/.
16. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
17. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
18. Dahabreh I.J., Linardou H., Siannis F., Fountzilas G., Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008, 13:620-630.
19. Viani G.A., Afonso S.L., Stefano E.J., De Fendi L.I., Soares F.V. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007, 7:153.
20. Bria E., Cuppone F., Fornier M., et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008, 109:231-239.
21. Meade M.O., Richardson W.S. Selecting and appraising studies for a systematic review. Ann Intern Med 1997, 127:531-537.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
23. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
24. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
25. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H). J Clin Oncol.2007 ASCO Annual Meeting Proceedings Part I 2007;25:LBA513.
26. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
27. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
28. Suter T.M., Procter M., van V.D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
29. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 2006;100:General Session 2; Abstract 2.
30. Spielmann M, Roché H, Humblet Y, et al. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. Breast Cancer Res Treat 2007;106:Abstract 72.
31. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001, 61(Suppl 2):58-66.
32. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010. doi:10.1016/j.ijcard.2010.03.003. doi:10.1016/j.ijcard.2010.03.003.
33. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
34. Chen B., Peng X., Pentassuglia L., Lim C.C., Sawyer D.B. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7:114-121.
35. Jones A.L., Barlow M., Barrett-Lee P.J., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009, 100:684-692.
36. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001, 19:2587-2595.
37. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001, 19:37-43.
38. Ganz P.A., Hussey M.A., Moinpour C.M., et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 2008, 26:1223-1230.
39. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.